A 28-year-old woman with moderate persistent asthma presents to the outpatient clinic for routine follow-up. She reports using her rescue inhaler 3–4 times per week and experiences nocturnal symptoms twice weekly. According to current asthma management guidelines, what is the most common first-line controller medication prescribed in this scenario?

## First-Line Controller for Moderate Persistent Asthma **Key Point:** Inhaled corticosteroids (ICS) are the gold standard and most commonly prescribed first-line controller agent for all persistent asthma, regardless of severity [cite:GINA 2023]. ### Rationale for ICS Monotherapy 1. **Anti-inflammatory efficacy**: ICS directly suppress airway inflammation, the underlying pathophysiology of asthma. 2. **Safety profile**: When used at appropriate doses, ICS have minimal systemic side effects. 3. **Guideline recommendation**: GINA, NAEPP, and Indian guidelines universally recommend ICS as initial controller therapy for persistent asthma. 4. **Evidence base**: Multiple RCTs demonstrate superior outcomes with ICS compared to all other monotherapy options. ### Stepwise Asthma Management Algorithm ```mermaid flowchart TD A[Asthma Diagnosis]:::outcome --> B{Symptom Frequency?}:::decision B -->|Intermittent| C[SABA PRN only]:::action B -->|Persistent| D{Severity Assessment}:::decision D -->|Mild persistent| E[ICS low-dose]:::action D -->|Moderate persistent| F[ICS medium-dose ± LABA]:::action D -->|Severe persistent| G[ICS high-dose + LABA ± LTRA]:::action E --> H[Reassess in 2-4 weeks]:::action F --> H G --> H ``` **High-Yield:** The patient in this case has moderate persistent asthma (symptoms 3–4 times/week, nocturnal symptoms 2×/week). The most common starting regimen is ICS at medium dose, with consideration of ICS/LABA combination if inadequate control after 2–4 weeks. ### Why ICS Monotherapy is Most Common | Feature | ICS | LABA | LTRA | Theophylline | |---------|-----|------|------|---------------| | **First-line** | Yes | No (always with ICS) | No | No | | **Anti-inflammatory** | Excellent | No | Modest | No | | **Onset** | 2–4 weeks | 12–24 hours | 1–2 weeks | Hours | | **Systemic SE** | Minimal (inhaled) | Tremor, tachycardia | Rare | Narrow TI | | **Guideline rank** | 1st | 2nd (add-on) | 3rd (alternative) | Obsolete | **Clinical Pearl:** Even in moderate persistent asthma, ICS is started first. LABA is added only if ICS monotherapy fails to achieve control in 2–4 weeks, creating the ICS/LABA combination (Step 3).